Eglin c based drugs for treatment of disease
The present invention relates to eglin c variants which inhibit proteases, and in particular to eglin c mutants at adventitious contact sites. The present invention also relates to eglin c variants which comprise mutations in both adventitious contact sites and at reactive loop sites. The present invention further relates to methods of preparing the eglin c variants, and methods of using the eglin c variants for treatment of diseases including acute bacterial, viral, and fungal infections.
1. A composition comprising a protease inhibitor that is an eglin c variant, wherein the eglin c variant comprises SEQ ID NO.2 with the exception of an amino acid change at a position selected from the group consisting of Asp33, Tyr35, Leu37, Glu39, Gly40, Leu47, Tyr49, Asn50, His65 and His68.
2. The composition of claim 1 , said amino acid change is Tyr49Asp.
3. The composition of claim 1 , wherein said amino acid change is Asp33Val.
4. A composition comprising a protease inhibitor that is an eglin c variant, wherein the eglin c variant comprises at least one at least one amino acid change at a position selected from the group consisting of Asp33, Tyr35, Leu37, Glu39, Gly40, Leu47, Tyr49, Asn50, His65 and His68 of SEQ ID NO:2, and further comprising at least one amino acid change at a position selected from the group consisting of Gly40, Ser41, Pro42, Val43, Thr44 and Arg45 of SEQ ID NO:2.
5. The composition of claim 4 , wherein said amino acid change is selected from the group consisting of Pro42Arg and Arg45Lys.
6. A composition comprising a protease inhibitor that is an eglin c variant, wherein the eglin c variant is selected from the group consisting of eglin c variants R4-, M4R1-, R4R1-, M4K1-, R4K1-, R6R4F1-, K2R1-, M4K2R1-, R4,K2R1-eglin, wherein the variant further comprises at least one amino acid chance at a position selected from the group consisting of Asp33, Tyr35, Leu37, Glu39, Gly40, Leu47, Tyr49, Asn50, His65 and His68 of SEQ ID NO:2.
7. The composition of claim 6 , wherein the eglin c variant inhibitor is selected from the group consisting of R4R1- and R4K1-eglin.
8. The composition of claim 6 , wherein the eglin c variant inhibitor is selected from the group consisting of R4R1- and R4K1-eglin.
9. The composition of claim 8 , wherein the eglin c variant is selected from the group consisting of R4R1- and R4K1-eglin, and wherein said eglin c variant further comprises an amino acid change selected from the group consisting of Asp replacing Tyr49, Val replacing Asp33, and both Asp replacing Tyr49 and Val replacing Asp33.
10. The composition of claim 9 , wherein the eglin c variant is R4R1-eglin, and and wherein said eglin c variant further comprises Asp replacing Tyr49 and Val replacing Asp33.